These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 35326339)

  • 1. Opicapone Improves Global Non-Motor Symptoms Burden in Parkinson's Disease: An Open-Label Prospective Study.
    Santos García D; Fernández Pajarín G; Oropesa-Ruiz JM; Escamilla Sevilla F; Rahim López RRA; Muñoz Enríquez JG
    Brain Sci; 2022 Mar; 12(3):. PubMed ID: 35326339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safinamide Improves Non-Motor Symptoms Burden in Parkinson's Disease: An Open-Label Prospective Study.
    Santos García D; Labandeira Guerra C; Yáñez Baña R; Cimas Hernando MI; Cabo López I; Paz Gonález JM; Alonso Losada MG; González Palmás MJ; Martínez Miró C
    Brain Sci; 2021 Mar; 11(3):. PubMed ID: 33801565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and safety of opicapone in Parkinson's disease patients with motor fluctuations: the OPTIPARK open-label study.
    Reichmann H; Lees A; Rocha JF; Magalhães D; Soares-da-Silva P;
    Transl Neurodegener; 2020 Mar; 9(1):9. PubMed ID: 32345378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of Global Non-Motor Symptoms Burden Progression in Parkinson's Disease. Results from the COPPADIS Cohort at 2-Year Follow-Up.
    Santos-García D; de Deus T; Cores C; Canfield H; Paz González JM; Martínez Miró C; Valdés Aymerich L; Suárez E; Jesús S; Aguilar M; Pastor P; Planellas L; Cosgaya M; García Caldentey J; Caballol N; Legarda I; Hernández-Vara J; Cabo I; López Manzanares L; González Aramburu I; Ávila Rivera MA; Catalán MJ; Nogueira V; Puente V; Dotor J; Borrué C; Solano B; Álvarez Sauco M; Vela L; Escalante S; Cubo E; Carrillo F; Martínez Castrillo JC; Sánchez Alonso P; Alonso G; López Ariztegui N; Gastón I; Kulisevsky J; Blázquez M; Seijo M; Rúiz Martínez J; Valero C; Kurtis M; de Fábregues O; Ardura J; Alonso R; Ordás C; López Díaz LM; McAfee D; Martinez-Martin P; Mir P; Coppadis Study Group
    J Pers Med; 2021 Jun; 11(7):. PubMed ID: 34209166
    [No Abstract]   [Full Text] [Related]  

  • 5. The real-life effect of catechol-O-methyltransferase inhibition on non-motor symptoms in levodopa-treated Parkinson's disease: opicapone versus entacapone.
    Leta V; van Wamelen DJ; Aureli F; Metta V; Trivedi D; Cortelli P; Rodriguez-Blazquez C; Rizos A; Ray Chaudhuri K
    J Neural Transm (Vienna); 2023 Jul; 130(7):925-930. PubMed ID: 37036498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opicapone versus placebo in the treatment of Parkinson's disease patients with end-of-dose motor fluctuation-associated pain: rationale and design of the randomised, double-blind OCEAN (OpiCapone Effect on motor fluctuations and pAiN) trial.
    Chaudhuri KR; Odin P; Ferreira JJ; Antonini A; Rascol O; Kurtis MM; Storch A; Bannister K; Soares-da-Silva P; Costa R; Magalhães D; Rocha JF
    BMC Neurol; 2022 Mar; 22(1):88. PubMed ID: 35279112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opicapone Use in Clinical Practice across Germany: A Sub-Analysis of the OPTIPARK Study in Parkinson's Disease Patients with Motor Fluctuations.
    Reichmann H; Eggert K; Oehlwein C; Warnecke T; Lees AJ; Kemmer M; Soares-da-Silva P
    Eur Neurol; 2022; 85(5):389-397. PubMed ID: 35350024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of non-motor symptoms on the quality of life of Parkinson's disease patients: a longitudinal study.
    Prakash KM; Nadkarni NV; Lye WK; Yong MH; Tan EK
    Eur J Neurol; 2016 May; 23(5):854-60. PubMed ID: 26806538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Motor Fluctuations Development Is Associated with Non-Motor Symptoms Burden Progression in Parkinson's Disease Patients: A 2-Year Follow-Up Study.
    Santos-García D; de Deus Fonticoba T; Bartolomé CC; Painceiras MJF; Castro ES; Canfield H; Miró CM; Jesús S; Aguilar M; Pastor P; Planellas L; Cosgaya M; Caldentey JG; Caballol N; Legarda I; Hernández-Vara J; Cabo I; Manzanares LL; Aramburu IG; Rivera MAÁ; Mayordomo VG; Nogueira V; Puente V; García-Soto JD; Borrué C; Vila BS; Sauco MÁ; Vela L; Escalante S; Cubo E; Padilla FC; Castrillo JCM; Alonso PS; Losada MGA; Ariztegui NL; Gastón I; Kulisevsky J; Estrada MB; Seijo M; Martínez JR; Valero C; Kurtis M; de Fábregues O; Ardura JG; Redondo RA; Ordás C; Díaz LML; McAfee D; Martinez-Martin P; Mir P; Coppadis Study Group
    Diagnostics (Basel); 2022 May; 12(5):. PubMed ID: 35626303
    [No Abstract]   [Full Text] [Related]  

  • 10. Vortioxetine Improves Depressive Symptoms and Cognition in Parkinson's Disease Patients with Major Depression: An Open-Label Prospective Study.
    Santos García D; Alonso Losada MG; Cimas Hernando I; Cabo López I; Yáñez Baña R; Alonso Redondo R; Paz González JM; Cores Bartolomé C; Feal Painceiras MJ; Íñiguez Alvarado MC; Labandeira C; García Díaz I
    Brain Sci; 2022 Oct; 12(11):. PubMed ID: 36358393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and Factors Associated with Drooling in Parkinson's Disease: Results from a Longitudinal Prospective Cohort and Comparison with a Control Group.
    Santos-García D; de Deus Fonticoba T; Cores Bartolomé C; Feal Painceiras MJ; Íñiguez-Alvarado MC; Jesús S; Buongiorno MT; Planellas L; Cosgaya M; García Caldentey J; Caballol N; Legarda I; Hernández Vara J; Cabo I; López Manzanares L; González Aramburu I; Ávila Rivera MA; Gómez Mayordomo V; Nogueira V; Puente V; Dotor García-Soto J; Borrué C; Solano Vila B; Álvarez Sauco M; Vela L; Escalante S; Cubo E; Carrillo Padilla F; Martínez Castrillo JC; Sánchez Alonso P; Alonso Losada MG; López Ariztegui N; Gastón I; Kulisevsky J; Blázquez Estrada M; Seijo M; Rúiz Martínez J; Valero C; Kurtis M; de Fábregues O; González Ardura J; Alonso Redondo R; Ordás C; López Díaz LML; McAfee D; Martinez-Martin P; Mir P; Coppadis SG
    Parkinsons Dis; 2023; 2023():3104425. PubMed ID: 37065970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of rotigotine transdermal patch in patients with Parkinson's disease presenting with non-motor symptoms - results of a double-blind, randomized, placebo-controlled trial.
    Antonini A; Bauer L; Dohin E; Oertel WH; Rascol O; Reichmann H; Schmid M; Singh P; Tolosa E; Chaudhuri KR
    Eur J Neurol; 2015 Oct; 22(10):1400-7. PubMed ID: 26095948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal evolution of non-motor symptoms in early Parkinson's disease: a 3-year prospective cohort study.
    Ou R; Hou Y; Wei Q; Lin J; Liu K; Zhang L; Jiang Z; Cao B; Zhao B; Song W; Shang H
    NPJ Parkinsons Dis; 2021 Jul; 7(1):58. PubMed ID: 34267217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life.
    Honig H; Antonini A; Martinez-Martin P; Forgacs I; Faye GC; Fox T; Fox K; Mancini F; Canesi M; Odin P; Chaudhuri KR
    Mov Disord; 2009 Jul; 24(10):1468-74. PubMed ID: 19425079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non motor symptoms in progressive supranuclear palsy: prevalence and severity.
    Radicati FG; Martinez Martin P; Fossati C; Chaudhuri KR; Torti M; Rodriguez Blazquez C; Vacca L; Stocchi F
    NPJ Parkinsons Dis; 2017; 3():35. PubMed ID: 29238748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of non-motor symptoms on the Health-Related Quality of Life of Parkinson's disease patients from Southwest China.
    Song W; Guo X; Chen K; Chen X; Cao B; Wei Q; Huang R; Zhao B; Wu Y; Shang HF
    Parkinsonism Relat Disord; 2014 Feb; 20(2):149-52. PubMed ID: 24161377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term safety and efficacy of opicapone in Japanese Parkinson's patients with motor fluctuations.
    Takeda A; Takahashi R; Tsuboi Y; Nomoto M; Maeda T; Nishimura A; Yoshida K; Hattori N
    J Neural Transm (Vienna); 2021 Mar; 128(3):337-344. PubMed ID: 33630140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gender and onset age related-differences of non-motor symptoms and quality of life in drug-naïve Parkinson's disease.
    Hu T; Ou R; Liu H; Hou Y; Wei Q; Song W; Cao B; Chen Y; Yuan X; Shang H
    Clin Neurol Neurosurg; 2018 Dec; 175():124-129. PubMed ID: 30408646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of Safinamide over Mood in Parkinson's Disease Patients: Secondary Analysis of the Open-label Study SAFINONMOTOR.
    Labandeira CM; Alonso Losada MG; Yáñez Baña R; Cimas Hernando MI; Cabo López I; Paz González JM; Gonzalez Palmás MJ; Martínez Miró C; Santos García D
    Adv Ther; 2021 Oct; 38(10):5398-5411. PubMed ID: 34523075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum Uric Acid Levels and Non-Motor Symptoms in Parkinson's Disease.
    van Wamelen DJ; Taddei RN; Calvano A; Titova N; Leta V; Shtuchniy I; Jenner P; Martinez-Martin P; Katunina E; Chaudhuri KR
    J Parkinsons Dis; 2020; 10(3):1003-1010. PubMed ID: 32444561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.